BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » drug discovery

How Human iPSCs are Revolutionizing Drug Discovery in 2022

May 3, 2022 By Cade Hildreth (CEO) Leave a Comment

ipsc drug discovery

Drug discovery involves high cost and uncertain outcomes.  Only a few companies can take the risk of investing enormous amounts of money into research and testing, only to see undesirable side effects emerge during the final human clinical trials. In many cases, companies are spending millions of dollars to fail during clinical testing.

Now, some new medicines are being tested for safety on specialized cells developed from human pluripotent cell lines. Cell types which are frequently being using within drug discovery applications include heart (cardiomyocytes) and liver cells (hepatocytes), which are the organs where 80% of drug failures occur. [Read more…]

Filed Under: iPS Cells Tagged With: drug discovery

Harnessing iPS Cells for Drug Development and Discovery

August 15, 2017 By Cade Hildreth (CEO) Leave a Comment

iPS Cells for Drug Development & Discovery

Since the discovery of induced pluripotent stem cells (iPS cells) in 2006, a great deal of basic research has been done to understand how to produce, manipulate, and utilize the cell type. iPS cells are revolutionizing regenerative medicine, because they represent a potential route for producing patient-specific stem cells for research applications or clinical use. iPS cells also show great promise for phamaco-toxicological screening, by allowing disease modeling and safety assessment of potential new drugs.

iPS Cells in Drug Discovery and Disease Modeling

iPS Cells for Drug DiscoveryiPS cells have the potential to transform drug discovery by providing physiologically relevant human cells for compound identification, target validation, compound screening, and tool discovery. They can be used to produce a wide variety of mature human cell types, allowing potential drug compounds to be screened in high-throughput systems using human cells.

Additionally, iPS cells allow for the creation of patient specific cell populations, facilitating in vitro drug testing that replicates the disease conditions of the patient population of interest.  This approach facilitates early determination of whether a specific genetic population will respond well to a drug candidate, a process known as “personalized medicine.”

Currently, all but one of the clinical trials underway with iPS cells involve the creation and evaluation of iPS cell lines from specific patient population to determine whether the cell lines will be a good model for a disease of interest in a specific patient population. The only exception to this is Cynata’s clinical trial underway for GvHD in the UK that involves a MSC-derived iPS cell product. [Read more…]

Filed Under: iPS Cells Tagged With: drug discovery, iPS cells

Pluriomics BV Partners to Offer Ultra-High Throughput Screening for Cardiovascular Drug Discovery Services

May 30, 2017 By Cade Hildreth (CEO) Leave a Comment

Pluriomics BV partners with Pivot Park Screening Centre

PluriomicsLeiden and Oss, The Netherlands, May 30th, 2017 – Pluriomics and Pivot Park Screening Centre announced a collaboration to improve Pluriomics’ cardiovascular drug discovery service offerings and to expand Pivot Park Screening Centre’s knowledge about new and innovative assay technologies used to accelerate drug discoveries. Giving Pluriomics access to the Screening Centre’s ultra High Throughput Screening (uHTS) capability, this collaboration will serve Pluriomics’ mission which is to contribute to the efficiency of the drug discovery and development process by reducing the development length, costs and late stage attrition of novel drug candidates.

[Read more…]

Filed Under: Stem Cells Tagged With: cardiovascular, cardiovascular stem cells, drug discovery, Pivot Park Screening Centre, Pluriomics

Pluriomics Awarded €3.2M to Advance Cardiovascular Drug Discovery – Reducing Time, Cost, & Late Stage Attrition of Drug Candidates

June 16, 2016 By Cade Hildreth (CEO) Leave a Comment

Pluriomics Awarded €3.2M to Advance Cardiovascular Drug Discovery - Reducing Time, Cost, & Late Stage Attrition of Drug Candidates

Pluriomics is a Dutch company that specializes in the “production and industrialization of high-quality, fully functional hiPS cells-derived cardiovascular cell types and on the development and realization of electrophysiology-, biochemistry- and contraction-based assays for predictive safety pharmacology, toxicology testing and efficacy screening.”

In news released today, the company announced that it will receive a €3.2M grant under the Horizon 2020 SME instrument programme to advance cardiovascular drug discovery.

The company also announced last month that it will lead a €2.0 million Eurostars consortium for the development of a novel in vitro organ-on-a-chip heart failure model for drug discovery and development.

To learn more about the €3.2M grant under the Horizon 2020 SME instrument programme, read the full press release below, printed with permission from Celine Hechard, PhD, VP Business Development & Marketing at Pluriomics. [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: cardiomyocytes, drug discovery, iPSC, Pluriomics

Axiogenesis Supports CiPA’s Aim to Improve Current Regulatory Guidances

June 12, 2016 By Cade Hildreth (CEO) Leave a Comment

Axiogenesis Supports CiPA’s Aim to Improve Current Regulatory Guidances

In 2006, induced pluripotent stem cells (iPSCs) were first introduced by Shinya Yamanaka at Kyoto University in Japan. Yamanaka’s discovery, which earned him the Nobel prize in 2012, enabled the use of human cells in stem cell science, bypassing the use of embryonic stem cells (ESCs). As a result of this advance, one of the most important applications for induced pluripotent stem cells has become their use as predictive technologies to support and streamline drug safety testing. [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: Axiogenesis, CiPA, drug discovery, iPSC

  • 1
  • 2
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.